DelveInsight has launched a new report on “Critical Limb Ischemia – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Critical Limb Ischemia – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Critical Limb Ischemia, historical and forecasted epidemiology as well as the Critical Limb Ischemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Critical Limb Ischemia Market Report:
-
As per the study conducted by Fereydooni et al. (2020), there are 6.5 million patients with critical limb ischemia in the US, Europe, and Japan based on global population-based studies.
-
The prevalence and cost of CLI are expected to increase with both the aging of the U.S. population and the continued influence of smoking and diabetes (Levin et al., 2019).
-
As per the study conducted by Mafilios (2019), CLI prevalence in the US adult population aged 40 or older is estimated to be 1.28%. With approximately 156 million US citizens in this age category, this prevalence estimate translates to approximately 2 million total CLI patients in the United States.
Key benefits of the report:
-
Critical Limb Ischemia market report covers a descriptive overview and comprehensive insight of the Critical Limb Ischemia Epidemiology and Critical Limb Ischemia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
-
The Critical Limb Ischemia market report provides insights on the current and emerging therapies.
-
Critical Limb Ischemia market report provides a global historical and forecasted market covering drug outreach in 7MM.
-
The Critical Limb Ischemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Critical Limb Ischemia market.
Got queries? Click here to know more about the Critical Limb Ischemia Market Landscape.
Critical Limb Ischemia Overview
Critical Limb Ischemia is a severe occlusion of the arteries that results in extreme pain and even skin ulcers or sores in the extremities (hands, feet, and legs). The discomfort from CLI might keep a person awake at night. This pain, often known as “rest pain,” usually occurs in the leg and can be briefly eased by hanging the leg over the edge of the bed or getting up to walk around.
Critical Limb Ischemia Market
The dynamics of the Critical Limb Ischemia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Ixaka Ltd., Hemostemix, Caladrius Biosciences, Inc., BioGenCell Ltd., and others during the forecasted period 2018-2030.
Learn more by requesting for sample @ Critical Limb Ischemia Market Landscape
Critical Limb Ischemia Pipeline Therapies and Key Companies
-
REX-001: Ixaka Ltd.
-
ACP-01: Hemostemix
-
CLBS12: Caladrius Biosciences, Inc.
-
BGC101: BioGenCell Ltd.
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Critical Limb Ischemia Patient Share (%) Overview at a Glance
5. Critical Limb Ischemia Market Overview at a Glance
6. Critical Limb Ischemia Disease Background and Overview
7. Critical Limb Ischemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Critical Limb Ischemia
9. Critical Limb Ischemia Current Treatment and Medical Practices
10. Unmet Needs
11. Critical Limb Ischemia Emerging Therapies
12. Critical Limb Ischemia Market Outlook
13. Country-Wise Critical Limb Ischemia Market Analysis (2018–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Critical Limb Ischemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/